Ceramide test in patients with erectile dysfunction to assess cardiovascular risk
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdaf182 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Andres Guillen Lozoya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States. Hauptthemen laut MEDLINE: Ceramides, Erectile Dysfunction, Cardiovascular Diseases. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Erectile dysfunction (ED) is a known precursor and sequela of cardiovascular disease (CVD), with ED severity predicting CVD severity.
Aim
This study aimed to evaluate the utility of ceramide levels in patients with ED.
Methods
We initiated ceramide testing in all patients with ED. We retrospectively analyzed ceramide levels from electronic records and stratified by severity of symptoms using the erectile function domain of the International Index of Erectile Function (IIEF). Outcomes The study aimed to determine whether abnormal ceramide levels were associated with ED severity and increased cardiovascular risk.
Results
Three hundred and fifty-four patients were reviewed, of whom 253 (71.5%) had moderate or higher ED. A statistically significant difference in abnormal ceramide values was found in patients with moderate to severe symptoms, and the odds of getting an abnormal ceramide test were increased based on the IIEF scoring alone (odds ratio [OR] 2.3 [1.04-5.12]; P-value = .034). Clinical Implications Serum ceramide testing could be beneficial in identifying cardiovascular risk in men with ED, potentially prompting cardiac referrals and lifestyle modifications. Strengths and Limitations The strengths of this study include a large sample size and the use of a well-established scale, while the limitations include the retrospective nature of the study and the need for further research to validate the findings.
Conclusion
Patients undergoing management for ED may benefit from serum ceramide testing and subsequent cardiac referral.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States.
- Mayo Clinic Alix School of Medicine, Rochester, Minnesota, 55905, United States.
- Department of Urology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States.
- Department of Cardiology, Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States.
ORCID-Profile: Andres Guillen Lozoya
Zitieren
APA
Guillen Lozoya, A., Dumbrava, M., Bonakdarhashemi, M., Kemble, J., Helo, S., Ziegelmann, M., Collins, S., Vasile, V., Kopecky, S., & Köhler, T. (2025). Ceramide test in patients with erectile dysfunction to assess cardiovascular risk. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf182
Vancouver
Guillen Lozoya A, Dumbrava M, Bonakdarhashemi M, Kemble J, Helo S, Ziegelmann M, et al. Ceramide test in patients with erectile dysfunction to assess cardiovascular risk. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf182
BibTeX
@article{GuillenLozoya2025,
author = {Guillen Lozoya, Andres and Dumbrava, Mihai and Bonakdarhashemi, Milad and Kemble, Jayson and Helo, Sevann and Ziegelmann, Matthew and Collins, Scott and Vasile, Vlad and Kopecky, Stephen and Köhler, Tobias},
title = {Ceramide test in patients with erectile dysfunction to assess cardiovascular risk},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdaf182}
}
EUVIMED